ABI 01
Alternative Names: ABI-01Latest Information Update: 25 Sep 2024
At a glance
- Originator Avanti Biosciences
- Class Antifibrotics; Catechins; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
- Discontinued Alzheimer's disease
Most Recent Events
- 10 Sep 2024 Discontinued for Alzheimer's disease in USA (unspecified route) prior to September 2024 (Avanti Biosciences pipeline, September 2024)
- 10 Sep 2024 Preclinical trials in Idiopathic pulmonary fibrosis in USA (unspecified route) (Avanti Biosciences pipeline, September 2024)
- 28 Jun 2024 No recent reports of development identified for research development in Alzheimer's-disease in USA